Fool.com
The World's Greatest Investing Community
Results 1 - 10 of 300 : 1 2 3 4 5 6 7 8 9 Next
After Rising 500%, What Did You Expect?
A nice licensing deal, but the stock was too high to begin with.
Abbott Makes All the Right Moves
You've got to know when to hold 'em and know when to fold 'em.
Merck Makes a Mark on Good Cholesterol
Can't profit from fighting bad lipoproteins? Start boosting the good ones.
A Mostly Meaningless FDA Approval
After an accelerated approval, the positive effects of a full approval are minimal.
A month into an acquisition, and Merck already sees a benefit.
It won't be a tough decision for patients to make.
Drug Lowers Cholesterol; Stock Follows
ISIS has a hard time at AHA despite good efficacy data.
Music to Health-Care Investors' Ears
Are faster FDA review times coming?
Abbott Puts a Nail in Merck's Coffin
There's a clear winner from the American Heart Association conference.
The company makes a deal that could pay off big, but could flame out instead.
Legal Information © 1995 - 2009 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK